Regulatory requirements for Drug master file in context to Canada and Australia
Drug Master Files are required in most countries as supporting documents for the registration of drug products. DMFs generally contain information pertaining to the chemistry, manufacturing and controls (CMC) sections of the drug submission and reflect the drug’s identity, strength, purity and quality. Canada and Australia which are consider as highly regulated markets (HRMs). In CANADA, DMF filing was done through New Drug Submission (NDS) for both drugs and biologic products. They use MF terminology for DMF which contain four types of MASTER FILE- ASMFs, CCS MFs, Excipient MFs, Drug product MFs. In AUSTRALIA different application processes and regulatory requirements apply depending on the type of therapeutic goods that is applied. They consist of eight phase for DMF registration. Where EU guidelines adopted in Australia include references to EU legislation. Now from 2016 onwards most of the regulated countries will use eCTD or their electronic format for their DMF submission. Compare DMF regulatory requirements in the above-mentioned countries so that reader can have clear idea on how to file DMF.
2. Akram MV, Nagarjuna, D Ramaiah M, Nagabhushanam M and Venkateswarlu B. Regulatory Requirements of Drug Master Files by Food and Drug Administration (USA). European Medicines Agency (Europe) and Health Canada (Canada) and their Comparison. Int. Glob. Phrm. Sci. 2014; 2220-24.
3. Drug Master File- Wikipedia [Internet]. Wikipedia; 2018 Mar [cited 2018 Mar 26]. Available from:
4. 2011 Fall Report of the Auditor General of Canada [Internet].2011 [cited 2018 Jan 18] Available from: http://www.oagbvg.gc.ca/internet/English/parloag20111104e35936.html
5. Therapeutic Goods Administration (TGA) [Internet]. Australia: TGA [cited 2018 Mar 12]. Available from: https://www.tga.gov.au/how-tga-regulates
6. Draft Guidance Document: Master Files (MFs) - Procedures and Administrative Requirements. [Internet]. Health Canada; 2016 Feb 15[cited 2018 Feb 10]. Available from:
7. Guidance Document: Preparation of Drug Regulatory Activities in the Common Technical Document (CTD) Format [Internet]. Health Canada; 2015 May [cited 2018 Feb 21]. Available from:
https://www.canada.ca/en/health-canada/ services/ drugs-health-products/drug-products/ applications-submissions/guidance-documents/ common-technical -document/preparation-drug-regulatory-activities-common-technical-document -format.html
8. Mallu UR, Kuraka AK and Bapatu HR. Pharmaceutical drug products approval procedure in Australia. Int. J. Sat. 2013; (3):690-705.
9. Gurram I, Kavitha MV, Reddy N, Nagabhushanam MV. Drug Master File Filing in US, Europe, Canada and Australia. J. Phrm. Res. 2017; p 160.
10. Raghucharan Y, Reddy LM, Bukke VN, Sundaram AM and Reddy JP. Regulatory Requirements for the Approval of Generic Drugs and Compilation of Dossier for Australia (TGA). Int. J. Ph. 2014; 201-6.
11. CTD Module 1 Administrative information and prescribing information for Australia [Internet]. Australia TGA; 2015 Jul [cited 2018 Feb 24]. Available from:
12. Australian regulatory guidelines for prescription medicines (argpm) [Internet]. Australia TGA; 2018 [cited 2018 Feb 11]. Available from:
13. Guidance for Industry M4Q: The CTD — Quality [Internet]. ICH; 2001 Aug [cited 2018 Feb 14]. Available from:
14. ICH M4Q - Common Technical Document for the Registration of Pharmaceuticals for human use quality [Internet]. London: EMEA; 2003 Feb 20 [cited 2018 Feb 17]. Available from:
15. ICH M4E - Common Technical Document for The Registration of Pharmaceuticals for human use efficacy [Internet]. London: EMEA; 2003 Feb 20 [cited 2018 Feb 17]. Available from:
16. ICH M4S - Common Technical Document for The Registration of Pharmaceuticals For human Use: Safety [Internet]. London: EMEA; 2003 Feb 20 [cited 2018 Feb 17]. Available from:
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
Rights of Authors:
The International Journal of Drug Regulatory affairs. recognize the retention of the following:
- Patent and trademark rights and rights to any process or procedure described in the article.
- The right to photocopy or make single electronic copies of the article for their own personal use, including for their own classroom use, or for the personal use of colleagues, provided the copies are not offered for sale and are not distributed in a systematic way outside of their employing institution (e.g. via an e-mail list or public file server). Posting of an article on a secure network (not accessible to the public) within the author’s institution is permitted.
- The right, subsequent to publication, to use the article or any part thereof free of charge in a printed compilation of works of their own, such as collected writings or lecture notes.
Note: All copies, paper, electronic or other use, of the information must include an indication of the IJDRA copyright and a full citation of the journal source.
- If the article was prepared jointly with other author(s), the signing author has informed the co-author(s) of the terms of this copyright transfer and is signing on their behalf as their agent and represents that he or she is authorized to do so, then please confirm by checking the appropriate box following the signature line. The signing author shall bear the responsibility for designating the co-author(s) and must inform the IJDRA of any changes in authorship.
- If copyright is held by the employer, then the employer or an authorized representative of the employer must sign. If the author signs, it is understood that this is with the authorization of the employer and the employer’s acceptance of the terms of the transfer.
The author(s) warrant(s) that the article is the author’s original work and has not been published before. The author(s) warrant(s) that the article contains no libelous or other unlawful statements, and does not infringe on the rights of others. If excerpts from copyrighted works are included, the author(s) has (have) obtained or will obtain written permission from the copyright owners and will credit the source in the article.
Preprints: The author(s) must agree that if a prior version of this work (normally a preprint) has been posted to an electronic public server, they will not update and/or replace the prior version in order to make it identical in content to the final published version.